WHO ICTRP trial
JCOG1806: Avoid mastectomy using trastuzumab, pertuzumab and radiation study for…
JPRN-jRCTs031190129 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs031190129 |
|---|---|
| Public title | JCOG1806: Avoid mastectomy using trastuzumab, pertuzumab and radiation study for breast cancer |
| Scientific title | JCOG1806: Avoid mastectomy using trastuzumab, pertuzumab and radiation study for breast cancer - AMATERAS-BC |
| Primary sponsor | FUJISAWA Tomomi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Clinical T1-2N0M0, HER2 positive primary breast cancer |
| Interventions | Anti-HER2 therapy and chemotherapy is performed for clinical cT1-2N0M0 HER2 positive primary breast cancer. Primary chemotherapy + anti-HER2 therapy (1) AC/EC therapy + THP therapy AC/EC therapy (anthracycline + cyclophosphamide) followed… |
| Registration date | May 11, 2019 |
| Target size | 350 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: